Physician profile
Ryan Massay
NPI 1710326384
$7,335.46
in general payments reported to CMS, 2019-2025
28 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $1,529 · 2021: $3,061 · 2022: $2,226 · 2023: $18.67 · 2024: $32.25 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,751.91 | 2019-2023 | |
| Amgen INC. | $926.46 | 2019-2022 | |
| Ucb, INC. | $843.63 | 2019-2022 | |
| Lilly USA, LLC | $502.29 | 2019-2022 | |
| Janssen Biotech, INC. | $460.82 | 2021-2025 | Tremfya |
| Glaxosmithkline, LLC. | $409.14 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $249.33 | 2020-2022 | |
| Pfizer INC. | $219.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $219.60 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $213.32 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $175.98 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $175.65 | 2021-2025 | Tremfya |
| Genentech USA, INC. | $174.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $166.66 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $157.06 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.19 | 2019-2022 | |
| Sobi, INC | $136.01 | 2020-2022 | |
| Amarin Pharma, INC. | $108.36 | 2020-2022 | |
| Antares Pharma, INC. | $62.06 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $61.64 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $46.55 | 2022 | |
| Arbor Pharmaceuticals, INC. | $39.91 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $29.98 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.68 | 2022 | |
| Mallinckrodt Enterprises LLC | $12.09 | 2019 | |
| Currax Pharmaceuticals LLC | $11.41 | 2021 | |
| Almatica Pharma LLC | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Massay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.